P-tau217 in Early Disease Detection: True Biomarker Value or Diagnostic Mirage?
Pan-African Journal of Health and Psychological Sciences · 04.04.2026 · 2 (2)
DOI: 10.64261/ng288b81 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pan-African Journal of Health and Psychological Sciences, online erschienen am 04.04.2026. Verfasst von Divneet Kaur und 5 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Phosphorylated tau (p-tau217) at the threonine 217 site is considered to be one of the most sensitive and specific biomarkers of early Alzheimer’s disease (AD). But it is facing new evidence showing that p-tau217 is present in unexpectedly high levels in the brains of neonatal brains, which is problematic with regard to its diagnostic specificity in different age groups.
Methods
The analysis of the literature through a narrative was performed in PubMed/MEDLINE, Scopus, and Web of Science (2020-2025).
Results
The results suggest that in the neonatal brains the levels of p-tau 217 are equal or higher than in the AD brains without amyloid- 217 deposition, neurofibrillary tangles or neurodegeneration. During early stages, non-aggregative, transient, and reversible, p-tau217 is required to facilitate critical processes including axonal development, synaptogenesis, synaptic pruning and neural plasticity.
Discussion
These findings underline that p-tau217 is a developmental and disease-related form of tau. Use of fixed diagnostic thresholds without age contextualization can produce a greater risk of false-positive interpretation especially among pediatric or asymptomatic groups. Conclusion: p-tau217 is not a purely pathological biomarker to consider. It is important to have age-adjusted reference ranges, multimodal diagnostic frameworks, and clinical correlation in order to interpret them accurately. The identification of the physiological role of p-tau217 in developing the human brain will be more diagnostic and less misclassified in biomarker-based neurology.
Zitieren
APA
Kaur, D., Khan, M. N., Agarwal, O. P., Kaur, J., Malik, S. A., & Kumar, A. (2026). P-tau217 in Early Disease Detection: True Biomarker Value or Diagnostic Mirage?. Pan-African Journal of Health and Psychological Sciences, 2(2). https://doi.org/10.64261/ng288b81
Vancouver
Kaur D, Khan MN, Agarwal OP, Kaur J, Malik SA, Kumar A. P-tau217 in Early Disease Detection: True Biomarker Value or Diagnostic Mirage?. Pan-African Journal of Health and Psychological Sciences. 2026;2(2). doi:10.64261/ng288b81
BibTeX
@article{Kaur2026,
author = {Kaur, Divneet and Khan, MD Nasiruddin and Agarwal, Om Prakash and Kaur, Jasvir and Malik, Sheeza Ashraf and Kumar, Ashish},
title = {P-tau217 in Early Disease Detection: True Biomarker Value or Diagnostic Mirage?},
journal = {Pan-African Journal of Health and Psychological Sciences},
year = {2026},
volume = {2},
number = {2},
doi = {10.64261/ng288b81}
}
EUVIMED